| Abstrakt: |
A recent study conducted by researchers at the University of the Chinese Academy of Sciences in Hangzhou, China, has discovered a potent PROTAC degrader of Pin1 for the treatment of Acute Myeloid Leukemia (AML). Pin1 is a protein that is overexpressed and/or overactivated in many human cancers, including AML. The researchers found that the PROTAC degrader, called P1D-34, induced Pin1 degradation and exhibited strong anti-proliferative effects in AML cell lines. Additionally, P1D-34 was able to sensitize Bcl-2 inhibitor-resistant AML cells to treatment with the Bcl-2 inhibitor ABT-199. The study suggests that targeted Pin1 degradation could be a promising strategy for the treatment of AML. [Extracted from the article] |
